About ZYMVOL
ZYMVOL is a company based in Barcelona (Spain) founded in 2017 by Maria Fatima Lucas. ZYMVOL has raised $4.52 million across 9 funding rounds from investors including European Union, Faber and Elaia. ZYMVOL offers products and services including Enzyme Search Platform and In Silico Design. ZYMVOL operates in a competitive market with competitors including Imperagen, Nanosyn and DirectBio, among others.
- Headquarter Barcelona, Spain
- Founders Maria Fatima Lucas
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zymvol Biomodeling, S.L.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.52 M (USD)
in 9 rounds
-
Latest Funding Round
$3.13 M (USD), Seed
Feb 20, 2025
-
Investors
European Union
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ZYMVOL
ZYMVOL offers a comprehensive portfolio of products and services, including Enzyme Search Platform and In Silico Design.
Identifies enzymes via high-throughput virtual screening and 3D modeling.
Optimizes enzymes using physics-based computer simulations for efficiency.
People of ZYMVOL
Unlock access to complete
Unlock access to complete
Funding Insights of ZYMVOL
ZYMVOL has successfully raised a total of $4.52M across 9 strategic funding rounds. The most recent funding activity was a Seed round of $3.13 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ZYMVOL
ZYMVOL has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Faber and Elaia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in early-stage tech companies
|
Locked | Locked | Locked | |
|
Venture capital firm focused on early-stage investments
|
Locked | Locked | Locked | |
|
A venture capital firm focused on climate tech startups.
|
Locked | Locked | Locked |
Investor details for ZYMVOL
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ZYMVOL
Investment portfolio details for ZYMVOL
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ZYMVOL
Detailed financials for ZYMVOL
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zymvol Comparisons
Peer comparison for ZYMVOL
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ZYMVOL
ZYMVOL operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Imperagen, Nanosyn and DirectBio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An enzyme engineering platform is developed for drug development applications.
|
|
| Locked | Locked | Locked |
Preclinical CRO services in chemistry and biological assays are offered.
|
|
| Locked | Locked | Locked |
Pioneers CRISPR-based tools for accurate airborne virus monitoring in various settings.
|
Detailed competitors of ZYMVOL
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zymvol
Complete news archive for ZYMVOL
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ZYMVOL
ZYMVOL was founded in 2017 and raised its 1st funding round 1 year after it was founded.
ZYMVOL is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Maria Fatima Lucas is the current CEO of ZYMVOL. They have also founded this company.
ZYMVOL is a funded company, having raised a total of $4.52M across 9 funding rounds to date.
Provider of enzyme development designing, biocatalysis, and protein engineering services. It offers bioinformatics and molecular modeling to identify and optimize enzymes, reducing development time and the need for experimental tests. It provides IP schemes and rate in enzyme discovery and design campaigns.
ZYMVOL offers Enzyme Search Platform and In Silico Design.
ZYMVOL has 5 investors. Key investors include European Union, Faber, Elaia, Übermorgen Ventures, and EIC Fund.